SEC Filing Summary: Pieris Pharmaceuticals, Inc. (PIRS)
Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on March 1, 2022. The report serves to disclose the Company's financial results for the fiscal year ended December 31, 2021, via a press release furnished as Exhibit 99.1. Additionally, the filing includes a March 2022 Investor Presentation as Exhibit 99.2 under Regulation FD.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are not included in the source text provided for analysis.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the fiscal year ended December 31, 2021.
Guidance, Outlook, and Risks
Management commentary, guidance, and outlook details are located in the furnished Investor Presentation (Exhibit 99.2). The filing explicitly states that the information in Items 2.02 and 7.01, including the exhibits, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific fiscal year 2021 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Investor Presentation) for updated clinical trial timelines, pipeline milestones, and forward-looking guidance.
- Verify the Company's cash runway and burn rate based on the full financial statements referenced in the press release.
- Confirm any new regulatory developments or partnership announcements detailed in the exhibits.